GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2451236&ei=n4aaUtjHJIj_sgfnKQ&usg=AFQjCNGaXGLm-Bn8XQTpQZmDTSRn9pct1A
Gilead Sciences, Inc. Submits Supplemental New Drug Application To U.S. Food And Drug Administration For Truvada For Reducing Risk Of Acquiring HIV
Thursday, 15 Dec 2011 04:30pm EST
Gilead Sciences, Inc. announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the approval of once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults. The sNDA is based on the results of two placebo-controlled trials of Truvada as PrEP, sponsored by the U.S. National Institutes of Health (NIH) and the University of Washington. Several other clinical studies support the use of Truvada for HIV risk reduction.Â 
